Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review.
Valentina CastilloFernanda FigueroaKaroll González-PizarroPaz Jopia-ContrerasClaudia Ibacache-QuirogaPublished in: Foods (Basel, Switzerland) (2021)
Non-alcoholic fatty liver disease (NAFLD) is a chronic non-communicable disease, with a prevalence of 25% worldwide. This pathology is a multifactorial illness, and is associated with different risks factors, including hypertension, hyperglycemia, dyslipidemia, and obesity. Beside these predisposing features, NAFLD has been related to changes in the microbiota, which favor the disease progression. In this context, the modulation of the gut microbiota has emerged as a new therapeutic target for the prophylaxis and treatment of NAFLD. This review describes the changes in the gut microbiota associated with NAFLD and the effect of probiotics, prebiotics, and synbiotics on the gut microbiota, liver damage, anthropometric parameters, blood lipids, inflammation markers and insulin resistance in these patients.
Keyphrases
- end stage renal disease
- oxidative stress
- ejection fraction
- newly diagnosed
- blood pressure
- chronic kidney disease
- type diabetes
- metabolic syndrome
- risk factors
- insulin resistance
- body composition
- weight loss
- prognostic factors
- liver fibrosis
- body mass index
- patient reported outcomes
- fatty acid
- human health
- climate change
- combination therapy